Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425669 | 1.00 | TP53 (0.41) | TP53ALDH1A1GAASMN1; SMN2BRD4 | |
| SCHEMBL2639277 | 0.83 | TP53 (0.40) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL1911342 | 0.81 | TP53 (0.39) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL14305169 | 0.79 | TP53 (0.46) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL17118123 | 0.79 | TP53 (0.46) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL5543322 | 0.79 | GAA (0.47) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL358775 | 0.79 | GAA (0.47) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL15200264 | 0.79 | GAA (0.47) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL5822723 | 0.79 | BRD4 (0.44) | ALDH1A1GAASMN1; SMN2BRD4 | |
| SCHEMBL2948892 | 0.78 | TP53 (0.56) | TP53ALDH1A1GAASMN1; SMN2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101068825-B | Having a2A2-propynyl adenosine analogs with modified 5' -ribose groups for agonist activity | Univ Virginia Patent Found | 2013-05-08 | — | — | CN | disclosed |
| EP-1778712-B1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | Univ Virginia Patent Found (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8158604-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-7989431-B2 | 4-{3-[6-Amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester; for inflammation, such as organ, tissue or cell transplantation, angioplasty (PCTA), inflammation following ischemia/reperfusion, or grafting | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-06-09 | — | — | US | disclosed |
| CN-1357002-A | Compositions for treating inflammatory responses | UNIV VIRGINIA (US) | 2002-07-03 | — | — | CN | disclosed |
| EP-1194440-A2 | INDUCTION OF PHARMACOLOGICAL STRESS WITH ADENOSINE RECEPTOR AGONISTS | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6322771-B1 | PARENTERALLY ADMINISTERING TO A MAMMAL A PURINE DERIVATIVE TO DIAGNOSE CORONARY ARTERY STENOSIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2001-11-27 | — | — | US | disclosed |
| EP-1150991-A2 | COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010027185-A1 | Methods and compositions for treating inflammatory response | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2001-10-04 | — | — | US | disclosed |
| US-6232297-B1 | ADMINISTERING 4-AMINOPYRROLO(3,2-D)PYRIMIDINE DERIVATIVE AS ADENOSINE RECEPTOR ANTAGONIST | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2001-05-15 | — | — | US | disclosed |
| EP-1079860-A1 | NICOTINE IMMUNOGEN | Independent pharmaceutica AB (SE) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000078774-A2 | INDUCTION OF PHARMACOLOGICAL STRESS WITH ADENOSINE RECEPTOR AGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000044763-A2 | COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-1999061054-A1 | NICOTINE IMMUNOGEN | INDEPENDENT PHARMACEUTICA AB (SE) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | TP53 969/4885ALDH1A1 166/4885GAA 916/4885 |
| US-20010027185-A1 | Methods and compositions for treating inflammatory response | LTB4R2, ADORA2A, PTGES2 | TP53 3360/4885ALDH1A1 1787/4885GAA 1593/4885 |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | TP53 3828/4885ALDH1A1 680/4885GAA 3958/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | TP53 969/4885ALDH1A1 166/4885GAA 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.